Marshall Wace Portfolio holdings
Marshall Wace is a British firm that runs long/short hedge funds. Its strategies combine computer-driven and traditional company analysis, applied worldwide and mostly to long/short equity. Paul Marshall, formerly head of European equities at Mercury Asset Management, and Ian Wace, formerly head of equities trading at Deutsche Bank, founded it in 1997. In 2002 it launched TOPS, a system that gathers investment ideas from equity professionals and uses algorithms to turn them into stock portfolios. In 2015 Marshall Wace formed a long-term partnership with KKR, a private equity and credit investor that took an ownership interest in the firm.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.9B |
| 2 |
Costco
COST
|
+$907M |
| 3 |
AbbVie
ABBV
|
+$643M |
| 4 |
JPMorgan Chase
JPM
|
+$609M |
| 5 |
Bank of America
BAC
|
+$567M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Mercado Libre
MELI
|
+$528M |
| 3 |
Broadcom
AVGO
|
+$514M |
| 4 |
Sandisk
SNDK
|
+$507M |
| 5 |
Marvell Technology
MRVL
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 34.91% |
| 2 | Technology | 20.64% |
| 3 | Consumer Discretionary | 9.07% |
| 4 | Healthcare | 8.21% |
| 5 | Financials | 7.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1526
LeMaitre Vascular
LMAT
$1.78B
| $3.59M | ﹤0.01% |
37,402
-93,818
| -71% | -$9.6M |
2023 Q2
12 quarters
|
|
1527
Kirby Corp
KEX
$6.68B
| $3.57M | ﹤0.01% |
26,261
+23,461
| +838% | +$3.36M |
2026 Q1
1 quarter
|
|
1528
Lifeway Foods
LWAY
$316M
| $3.55M | ﹤0.01% |
118,944
-13,313
| -10% | -$339K |
2025 Q4
2 quarters
|
|
1529
New Found Gold
NFGC
$575M
| $3.54M | ﹤0.01% |
2,296,568
-140,438
| -6% | -$269K |
2024 Q2
8 quarters
|
|
1530
Smith & Wesson
SWBI
$698M
| $3.53M | ﹤0.01% |
235,008
+5,253
| +2% | +$78.9K |
2025 Q3
3 quarters
|
|
1531
VanEck Semiconductor ETF
SMH
$64.9B
| $3.52M | ﹤0.01% |
5,371
-171,386
| -97% | -$93.5M |
2026 Q1
1 quarter
|
|
1532
Vericel Corp
VCEL
$2.93B
| $3.51M | ﹤0.01% |
78,796
-127,873
| -62% | -$4.6M |
2025 Q4
2 quarters
|
|
1533
Cactus
WHD
$4.99B
| $3.5M | ﹤0.01% |
68,317
+61,017
| +836% | +$3.4M |
2025 Q4
2 quarters
|
|
1534
US Global Jets ETF
JETS
$913M
| $3.5M | ﹤0.01% |
+105,266
| New | +$2.91M |
2026 Q2
0 quarters
|
|
1535
SAP
SAP
$270B
| $3.49M | ﹤0.01% |
22,620
-174,771
| -89% | -$29.8M |
2025 Q3
3 quarters
|
|
1536
iShares MSCI Emerging Markets ex China ETF
EMXC
$25.5B
| $3.46M | ﹤0.01% |
33,813
-433,244
| -93% | -$40.9M |
2025 Q2
4 quarters
|
|
1537
Service Properties Trust
SVC
$720M
| $3.44M | ﹤0.01% |
407,406
+377,567
| +1,265% | +$2.97M |
2026 Q1
1 quarter
|
|
1538
Marqeta
MQ
$1.87B
| $3.43M | ﹤0.01% |
211,201
-230,552
| -52% | -$3.75M |
2024 Q2
8 quarters
|
|
1539
Choiceone Financial
COFS
$550M
| $3.43M | ﹤0.01% |
100,803
+15,704
| +18% | +$488K |
2025 Q3
3 quarters
|
|
1540
Annovis Bio
ANVS
$36.4M
| $3.43M | ﹤0.01% |
1,842,339
+654,840
| +55% | +$1.27M |
2025 Q4
2 quarters
|
|
1541
Dover
DOV
$27.9B
| $3.42M | ﹤0.01% |
15,258
+10,858
| +247% | +$2.37M |
2025 Q3
3 quarters
|
|
1542
The Mosaic Company
MOS
$6.92B
| $3.42M | ﹤0.01% |
161,352
-1,924,817
| -92% | -$44.5M |
2026 Q1
1 quarter
|
|
1543
Ellington Financial
EFC
$1.43B
| $3.42M | ﹤0.01% |
251,024
+235,255
| +1,492% | +$3.11M |
2024 Q3
7 quarters
|
|
1544
Hecla Mining
HL
$8.97B
| $3.41M | ﹤0.01% |
221,239
+172,950
| +358% | +$3.04M |
2026 Q1
1 quarter
|
|
1545
Albertsons Companies
ACI
$6.2B
| $3.4M | ﹤0.01% |
+251,159
| New | +$4.02M |
2026 Q2
0 quarters
|
|
1546
CALL
Corning
GLW
$103B
| $3.4M | ﹤0.01% |
+13,300
| New | +$2.42M |
2026 Q2
0 quarters
|
|
1547
ImmunityBio
IBRX
$6.46B
| $3.4M | ﹤0.01% |
387,700
+310,675
| +403% | +$2.35M |
2026 Q1
1 quarter
|
|
1548
FTI Consulting
FCN
$5.41B
| $3.39M | ﹤0.01% |
+22,749
| New | +$3.72M |
2026 Q2
0 quarters
|
|
1549
Saic
SAIC
$6.34B
| $3.39M | ﹤0.01% |
30,696
-3,389
| -10% | -$343K |
2026 Q1
1 quarter
|
|
1550
Bicycle Therapeutics
BCYC
$242M
| $3.38M | ﹤0.01% |
797,940
+420,605
| +111% | +$1.93M |
2025 Q4
2 quarters
|
|
Similar funds
Marshall Wace's Q2 2026 Portfolio in Review
As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.
By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.
- Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.9B increase.
- Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
- Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
- Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
- Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
- Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.